{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:21:45Z","timestamp":1787840505179,"version":"build-2784847793"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n                    Measurable residual disease (MRD) has established prognostic significance in patients with myeloid disorders; however, there is limited data regarding its prognostic and predictive value and the optimal technique for measurement in the setting of post allogeneic hematopoietic cell transplantation (allo-HCT). A multi-gene next generation sequencing (NGS) panel can overcome the limitations of conventional techniques for measurement of MRD and can shed light onto the longitudinal evolution and genomic complexity of patients undergoing allo-HCT for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In this study, patients with AML or MDS who underwent their first allo-HCT and completed NGS testing at day +100 and were in a state of morphological remission were identified from the transplant registry of Mayo Clinic in Florida. The primary aim was to evaluate the prognostic impact of somatic variants detected via NGS at day +100 post allo-HCT on long-term outcomes. In total, 105 patients who underwent allo-HCT for AML and MDS and completed NGS testing on day +100 were included in the study population. Seventeen patients were found to have detectable variants, and 88 patients were without a detectable variant. At a median follow up of 1.4 years (0.1\u20135.5), presence of any variant at day +100 was associated with inferior 4-year overall survival (OS) (32% vs. 69%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001), decreased progression free survival (PFS) (34% vs. 61%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001), and a higher incidence of relapse (64% vs. 23%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001). In univariate models, a lower Karnofsky performance score and presence of variants post allo-HCT remained significantly associated with inferior OS, higher relapse incidence, and a decreased PFS. The presence of variants at day +100 post allo-HCT remained significant in multivariate models for relapse (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u20090.002) but not for OS (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u20090.06) and PFS (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u20090.08). These results indicate that the presence of detectable somatic variants at day +100 is associated with poor long-term outcomes and are predictive of a higher incidence of relapse.\n                  <\/jats:p>","DOI":"10.4103\/hemoncstem.hemoncstem-d-25-00029","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:00:38Z","timestamp":1773820838000},"page":"155-163","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Somatic Variants Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome"],"prefix":"10.4103","volume":"18","author":[{"given":"Madiha","family":"Iqbal","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himil","family":"Mahadevia","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Blumenfeld","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Murthy","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Foran","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Badar","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Shan","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"R1-20260708","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"key":"R2-20260708","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"R3-20260708","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.path.2015.10.004","article-title":"Genetic testing in acute myeloid leukemia and myelodysplastic syndromes","volume":"9","author":"Nardi","year":"2016","journal-title":"Surg Pathol Clin"},{"key":"R4-20260708","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"key":"R5-20260708","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"R6-20260708","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"R7-20260708","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"R8-20260708","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"R9-20260708","doi-asserted-by":"crossref","first-page":"12475","DOI":"10.1038\/ncomms12475","article-title":"Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia","volume":"7","author":"Hirsch","year":"2016","journal-title":"Nat Commun"},{"key":"R10-20260708","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"R11-20260708","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.2015.9643","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia","volume":"314","author":"Klco","year":"2015","journal-title":"JAMA"},{"key":"R12-20260708","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat Commun"},{"key":"R13-20260708","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/s41409-022-01762-y","article-title":"Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"57","author":"Hong","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R14-20260708","doi-asserted-by":"crossref","first-page":"9853","DOI":"10.1038\/s41467-024-54254-6","article-title":"Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"R15-20260708","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"key":"R16-20260708","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1182\/blood-2023-190202","article-title":"Detectable somatic variants using next generation sequencing (NGS) post allogeneic hematopoietic cell transplant (Allo-HCT) predict for high relapse risk in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS","volume":"142","author":"Mahadevia","year":"2023","journal-title":"Blood"},{"key":"R17-20260708","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"R18-20260708","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1182\/bloodadvances.2022007168","article-title":"Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission","volume":"6","author":"Jentzsch","year":"2022","journal-title":"Blood Adv"},{"key":"R19-20260708","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","article-title":"The present and future of measurable residual disease testing in acute myeloid leukemia","volume":"107","author":"Blachly","year":"2022","journal-title":"Haematologica"},{"key":"R20-20260708","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/cancers11020252","article-title":"Next generation sequencing in AML-on the way to becoming a new standard for treatment initiation and\/or modulation?","volume":"11","author":"Leisch","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R21-20260708","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"R22-20260708","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv"},{"key":"R23-20260708","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-021-00500-9","article-title":"Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"11","author":"Kim","year":"2021","journal-title":"Blood Cancer J"},{"key":"R24-20260708","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"key":"R25-20260708","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"key":"R26-20260708","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"R27-20260708","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.hemoncstem-D-25-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:24:04Z","timestamp":1787837044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.hemoncstem-D-25-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/hemoncstem.hemoncstem-d-25-00029","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-07-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}